Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance

Abstract excerpt

Histone deacetylase inhibitors (HDACi) have shown promising activity against hematological malignancies in clinical trials and have led to the approval of vorinostat for the treatment of cutaneous T-cell lymphoma. However, de novo or acquired resistance to HDACi therapy is inevitable, and their molecular mechanisms are still unclear. To gain insight into HDACi resistance, we developed vorinostat-resistant clones...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Autophagy in Disease and Therapy
• Share to Histone Deacetylase Inhibitors Research
• Share to Viral-associated cancers and disorders